NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
78 trialsNCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT07123090 2026-02-27
SPARCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT03092856 2025-12-17
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Phase 2 Active not recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05363631 2025-12-10
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
Phase 1/2 Active not recruiting
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03826589 2025-06-11
ALARICE
The University of Hong Kong
Phase NA Completed
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02535533 2025-05-20
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1 Completed
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06889649 2025-03-21
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
Phase 2 Recruiting
NCT05808608 2025-01-27
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT04562441 2025-01-10
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase 2 Completed
NCT05941637 2024-12-31
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Lynkcell Europe
No longer available
NCT05904730 2024-12-30
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
Phase 1 Completed
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT06020352 2023-08-31
The Efficacy and Safety of KN046 Combined With Axitinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2/3 Unknown
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05816642 2023-04-18
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
RenJi Hospital
Phase NA Unknown
NCT04010071 2023-03-29
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT05070221 2021-10-07
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT02261207 2021-09-28
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04958473 2021-07-12
SAARCC
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT02762513 2021-05-05
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01140737 2021-03-18
Axi-STS
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed